ASHP BEST PRACTICES AWARD

Development and Implementation of an Oral Drug **Repository Program**

Athena C. Triglia, PharmD Jennifer Booth, PharmD, MS, BCPS Andre Fernandes, PharmD, MS, BCPS, BCSCP Kevin Wolowiec, PharmD Trisha Jordan, PharmD, MS Julie-Kennerly-Shah, PharmD, MS, MHA, BCPS

> The Ohio State University Wexner Medical Center Columbus, Ohio



Authors of this presentation disclose the following relationships with commercial interests related to the subject of this poster: Nothing to Disclose.

The Ohio State UNIVERSITY WEXNER MEDICAL CENTER

Introduction

The Ohio State University Wexner Medical Center

Department of Pharmacy Services

- 30 pharmacy locations
- 6 specialty/retail
- 7 oncology infusion
- 6 non-oncology infusion
- Acute Care and Emergency Department
- Specialty Retail and Home Delivery Pharmacy
- Medication Revenue Integrity Program
- Medication Management Program
- Investigational Drug Services

Background

- reuse
- As of 2021, only 12 states have a repository program specific to unused oral oncology drugs • Prior to 2019, oral oncology drugs were restricted for

Purpose



• Not for profit, academic medical center located on the main campus of The Ohio State University • Comprised of 7 hospitals, NCI Designated Comprehensive Cancer Center, Level I Trauma Center, and 20 outpatient clinic locations

• 2,000+ active research studies and clinical trials

- Subspecialized inpatient and ambulatory pharmacy
- practice model with privileged pharmacists

 91% of Americans think cancer drug costs are too high • Annually, approximately \$5 billion of unexpired drug is discarded, and the majority could be collected for

donation by the Ohio State Board of Pharmacy

• Our health-system recognized the opportunity to redispense medications to patients in need, increase medication adherence, prevent unused medication waste, and decrease overall healthcare costs by advocating for and developing an oral drug repository.

Description of the Program

Timeline

June 2019 Advocacy to	o Ohio	Legis
-----------------------	--------	-------

- Ohio Revised Code updated to allow oral oncology drug dispenses
- Jan 2020 OSU is Ohio's first oral oncology drug repository
- Feb 2020 First oral oncology drug dispense
- Jan 2023 Advocacy to Ohio Legislature for repository expansion
- Ohio Revised Code updated to allow non-Mar 2023 oncology drug dispenses

Medication Selection

- Oral oncology drugs are prioritized by cost, prescription volume, donation potential, urgency of medication need, and availability of alternative financial assistance
- Expert panels were used to assess patient obtainment difficulty
- Implementation started with two drugs:
- Capecitabine (Xeloda)
- Temozolomide (Temodar)
- The inventory has steadily increased to include over 40 oral oncology drugs since 2020

OSU Patient Eligibility Requirements

- Must reside within the state of Ohio and meet at least one of the following criteria:
- Either ineligible or denied grant access to drug • Either ineligible or denied medication assistance
- access to drug
- Either ineligible or denied insurance coverage access to drug
- Unable to gain access to drug through alternative financial means

OSU Drug Donation Eligibility Requirements

- Drug must meet all the following criteria: • Stored according to federal and state guidelines
- Packaging lists expiration date
- Expiration date of \geq 6 months
- No physical signs of adulteration
- Not a controlled substance or sample
- No associated REMs program
- Does not require cold storage

islature



Growth and Expansion Outcomes

- Since implementation in 2020, over 18,000 tablets/capsules of eligible oral oncology drugs have been accepted
- 141 prescriptions have been dispensed to eligible patients in need, with steady increases each year
- 103 unique patients have been positively impacted by receiving a prescription from this program
- 26 patients have received more than one prescription • 2,572 days (approximately 7 years) of free cancer therapy have been dispensed
- Repository dispenses to date are valued at \$1,003,753
- With recent updates to the Ohio Revised Code, OSU is following a similar process to expand to non-oncology



Growth and Expansion Outcomes

Oral Oncology Tablets/Capsules Dispensed



Significance of the Program

- Our pharmacists have participated in local, state, and national education surrounding the benefits, obstacles, and best practices associated with developing an oral drug repository program
- Program success led to pharmacist testimony to Ohio legislature and changes to the Ohio Revised Code to include non-oncology and refrigerated medications
- Deep gratitude from patients and family members for the ability to donate and help another patient

Conclusion

• The implementation of a drug repository program has dramatically reduced out-of-pocket costs for the patients within our community, decreased drug waste, and provided an opportunity for our pharmacists to advocate for expansion of the program to widen the impact of repository programs across the state.

Acknowledgements

- OSUWMC Department of Pharmacy
- Amanda Hafford, PharmD, MS
- Jeremy Peters, PharmD
- Lauren Stanz, PharmD, MS, BCPS

References

- . Hamel L. Public opinion on prescription drugs and their prices [Internet]. 2022 [cited 2023 Jul 4]. Available from: https://www.kff.org/health-costs/poll-finding/public-opinion-on-prescription-drugs-andtheir-prices/
- Parekh N, McClellan M, Shrank WH. Payment Reform, Medication Use, and Costs: Can We Afford to Leave Out Drugs? J Gen Intern Med. 2019 Mar;34(3):473-476. doi: 10.1007/s11606-018-4794-y. Epub 2019 Jan 2. PMID: 30604128; PMCID: PMC6420553.
- Van Alsten SC, Harris JK. Cost-Related Nonadherence and Mortality in Patients With Chronic Disease: A Multiyear Investigation, National Health Interview Survey, 2000-2014. Prev Chronic Dis. 2020 Dec 3;17:E151. doi: 10.5888/pcd17.200244. PMID: 33274701; PMCID: PMC7735485
- 2022 cancer facts & figures cancer: Cancer death rate drops [Internet]. 2022 [cited 2023 Jul 4].
- Available from: https://www.cancer.org/research/acs-research-news/facts-and-figures-2022.html Olszewski AJ, Zullo AR, Nering CR, et al: Use of charity financial assistance for novel oral anticancer agents. J Oncol Pract 14:e221-e228, 2018
- ASCO National Cancer Opinion Survey <u>PowerPoint Presentation (asco.org)</u>
- Olszewski AJ, Zullo AR, Nering CR, et al: Use of charity financial assistance for novel oral anticancer agents. J Oncol Pract 14:e221-e228, 2018
- Myshko D. The cost of new cancer drugs is increasing [Internet]. Formulary Watch; 2023 [cited 2023] Jul 5]. Available from: https://www.formularywatch.com/view/the-cost-of-new-cancer-drugs-is-
- Lenzer J: US could recycle 10 million unused prescription drugs a year, report says. BMJ 349:g7677, 2014